FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016046171> ?p ?o ?g. }

• W2016046171 endingPage "455" @default.
• W2016046171 startingPage "445" @default.
• W2016046171 abstract "Novel treatments such as natalizumab and fingolimod achieve their therapeutic efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the central nervous system, thus creating nonphysiological intrathecal immunity. In contrast, daclizumab, a humanized monoclonal antibody against the alpha chain of the IL-2 receptor, has a unique mechanism of action with multiple direct effects on innate immunity. As cellular intrathecal abnormalities corresponding to MS have been well defined, we asked how daclizumab therapy affects these immunological hallmarks of the MS disease process.Nineteen subpopulations of immune cells were assessed in a blinded fashion in the blood and 50-fold concentrated cerebrospinal fluid (CSF) cell pellet in 32 patients with untreated relapsing-remitting MS (RRMS), 22 daclizumab-treated RRMS patients, and 11 healthy donors (HDs) using 12-color flow cytometry.Long-term daclizumab therapy normalized all immunophenotyping abnormalities differentiating untreated RRMS patients from HDs. Specifically, strong enrichment of adaptive immune cells (CD4+ and CD8+ T cells and B cells) in the CSF was reversed. Similarly, daclizumab controlled MS-related increases in the innate lymphoid cells (ILCs) and lymphoid tissue inducer cells in the blood and CSF, and reverted the diminished proportion of intrathecal monocytes. The only marker that distinguished daclizumab-treated MS patients from HDs was the expansion of immunoregulatory CD56(bright) NK cells.Normalization of immunological abnormalities associated with MS by long-term daclizumab therapy suggests that this drug's effects on ILCs, NK cells, and dendritic cell-mediated antigen presentation to CD4+ and CD8+ T cells are critical in regulating the MS disease process." @default.
• W2016046171 created "2016-06-24" @default.
• W2016046171 creator A5004879108 @default.
• W2016046171 creator A5025945807 @default.
• W2016046171 creator A5031415251 @default.
• W2016046171 creator A5053465540 @default.
• W2016046171 creator A5068446590 @default.
• W2016046171 creator A5080215421 @default.
• W2016046171 date "2015-04-07" @default.
• W2016046171 modified "2023-09-25" @default.
• W2016046171 title "Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis" @default.
• W2016046171 cites W1486033940 @default.
• W2016046171 cites W1516581843 @default.
• W2016046171 cites W1538323547 @default.
• W2016046171 cites W1697418081 @default.
• W2016046171 cites W1967090255 @default.
• W2016046171 cites W1968846399 @default.
• W2016046171 cites W1975389005 @default.
• W2016046171 cites W1977213877 @default.
• W2016046171 cites W1977492688 @default.
• W2016046171 cites W1981671042 @default.
• W2016046171 cites W1984999645 @default.
• W2016046171 cites W1986297885 @default.
• W2016046171 cites W1996481500 @default.
• W2016046171 cites W2009570912 @default.
• W2016046171 cites W2015847142 @default.
• W2016046171 cites W2018505426 @default.
• W2016046171 cites W2028530728 @default.
• W2016046171 cites W2041192609 @default.
• W2016046171 cites W2050013893 @default.
• W2016046171 cites W2053553562 @default.
• W2016046171 cites W2053882591 @default.
• W2016046171 cites W2061771806 @default.
• W2016046171 cites W2064008763 @default.
• W2016046171 cites W2080463438 @default.
• W2016046171 cites W2092024887 @default.
• W2016046171 cites W2101684276 @default.
• W2016046171 cites W2113485611 @default.
• W2016046171 cites W2113754168 @default.
• W2016046171 cites W2114942536 @default.
• W2016046171 cites W2120042716 @default.
• W2016046171 cites W2122545833 @default.
• W2016046171 cites W2128948123 @default.
• W2016046171 cites W2135403800 @default.
• W2016046171 cites W2142577589 @default.
• W2016046171 cites W2150490856 @default.
• W2016046171 cites W2154468886 @default.
• W2016046171 cites W2154735816 @default.
• W2016046171 cites W2161607126 @default.
• W2016046171 cites W2164351607 @default.
• W2016046171 cites W2167414238 @default.
• W2016046171 cites W2169082675 @default.
• W2016046171 cites W2171375112 @default.
• W2016046171 cites W2413679075 @default.
• W2016046171 doi "https://doi.org/10.1002/acn3.181" @default.
• W2016046171 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4435700" @default.
• W2016046171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26000318" @default.
• W2016046171 hasPublicationYear "2015" @default.
• W2016046171 type Work @default.
• W2016046171 sameAs 2016046171 @default.
• W2016046171 citedByCount "38" @default.
• W2016046171 countsByYear W20160461712015 @default.
• W2016046171 countsByYear W20160461712016 @default.
• W2016046171 countsByYear W20160461712017 @default.
• W2016046171 countsByYear W20160461712018 @default.
• W2016046171 countsByYear W20160461712019 @default.
• W2016046171 countsByYear W20160461712020 @default.
• W2016046171 countsByYear W20160461712021 @default.
• W2016046171 countsByYear W20160461712022 @default.
• W2016046171 crossrefType "journal-article" @default.
• W2016046171 hasAuthorship W2016046171A5004879108 @default.
• W2016046171 hasAuthorship W2016046171A5025945807 @default.
• W2016046171 hasAuthorship W2016046171A5031415251 @default.
• W2016046171 hasAuthorship W2016046171A5053465540 @default.
• W2016046171 hasAuthorship W2016046171A5068446590 @default.
• W2016046171 hasAuthorship W2016046171A5080215421 @default.
• W2016046171 hasBestOaLocation W20160461711 @default.
• W2016046171 hasConcept C159654299 @default.
• W2016046171 hasConcept C167672396 @default.
• W2016046171 hasConcept C203014093 @default.
• W2016046171 hasConcept C2779719350 @default.
• W2016046171 hasConcept C2780640218 @default.
• W2016046171 hasConcept C2781004633 @default.
• W2016046171 hasConcept C542903549 @default.
• W2016046171 hasConcept C71924100 @default.
• W2016046171 hasConcept C8891405 @default.
• W2016046171 hasConceptScore W2016046171C159654299 @default.
• W2016046171 hasConceptScore W2016046171C167672396 @default.
• W2016046171 hasConceptScore W2016046171C203014093 @default.
• W2016046171 hasConceptScore W2016046171C2779719350 @default.
• W2016046171 hasConceptScore W2016046171C2780640218 @default.
• W2016046171 hasConceptScore W2016046171C2781004633 @default.
• W2016046171 hasConceptScore W2016046171C542903549 @default.
• W2016046171 hasConceptScore W2016046171C71924100 @default.
• W2016046171 hasConceptScore W2016046171C8891405 @default.
• W2016046171 hasFunder F4320337359 @default.
• W2016046171 hasIssue "5" @default.
• W2016046171 hasLocation W20160461711 @default.

• next